BR112022010021A2 - Compostos e composições para tratamento de distúrbios do sistema nervoso central (snc) - Google Patents

Compostos e composições para tratamento de distúrbios do sistema nervoso central (snc)

Info

Publication number
BR112022010021A2
BR112022010021A2 BR112022010021A BR112022010021A BR112022010021A2 BR 112022010021 A2 BR112022010021 A2 BR 112022010021A2 BR 112022010021 A BR112022010021 A BR 112022010021A BR 112022010021 A BR112022010021 A BR 112022010021A BR 112022010021 A2 BR112022010021 A2 BR 112022010021A2
Authority
BR
Brazil
Prior art keywords
compounds
treatment
disorders
cns
compositions
Prior art date
Application number
BR112022010021A
Other languages
English (en)
Inventor
L Spear Kerry
Burdi Douglas
Original Assignee
Blue Oak Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blue Oak Pharmaceuticals Inc filed Critical Blue Oak Pharmaceuticals Inc
Publication of BR112022010021A2 publication Critical patent/BR112022010021A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTOS E COMPOSIÇÕES PARA TRATAMENTO DE DISTÚRBIOS DO SISTEMA NERVOSO CENTRAL(SNC). A presente invenção fornece os compostos e composições farmacêuticas dos mesmos. Métodos de preparar e usar os compostos também são fornecidos. Os compostos podem ser usados para o tratamento, prevenção, diagnóstico e/ou gerenciamento de vários distúrbios de SNC.
BR112022010021A 2020-01-03 2020-12-29 Compostos e composições para tratamento de distúrbios do sistema nervoso central (snc) BR112022010021A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062956895P 2020-01-03 2020-01-03
US202063128375P 2020-12-21 2020-12-21
PCT/US2020/067298 WO2021138314A1 (en) 2020-01-03 2020-12-29 Compounds and compositions for treating cns disorders

Publications (1)

Publication Number Publication Date
BR112022010021A2 true BR112022010021A2 (pt) 2022-08-16

Family

ID=76687277

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010021A BR112022010021A2 (pt) 2020-01-03 2020-12-29 Compostos e composições para tratamento de distúrbios do sistema nervoso central (snc)

Country Status (9)

Country Link
US (1) US20230116114A1 (pt)
EP (1) EP4084797A4 (pt)
JP (1) JP2023509453A (pt)
KR (1) KR20220123406A (pt)
CN (1) CN114929235A (pt)
AU (1) AU2020416203A1 (pt)
BR (1) BR112022010021A2 (pt)
CA (1) CA3161867A1 (pt)
WO (1) WO2021138314A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2174771A1 (en) * 1972-03-10 1973-10-19 Roussel Uclaf 9-hydroxy 10,9-iminomethano anthracenes - sedatives or stimulants
FR2224146A2 (en) * 1973-04-09 1974-10-31 Roussel Uclaf 5,10-Imino dibenzo cycloheptenes - prepn from 12-unsubstituted imino dibenzo cycloheptenes - antidepressants anticonvulsants and sedatives
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
JP2007516275A (ja) * 2003-12-23 2007-06-21 ファイザー・プロダクツ・インク 認知増強および精神病性障害のための治療的組合せ
CA2619448C (en) * 2005-09-01 2013-08-13 Eli Lilly And Company 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
KR20110055715A (ko) * 2008-09-05 2011-05-25 엘란 파마슈티칼스, 인크. Ｎ-설폰아미도 폴리사이클릭 피라졸릴 화합물

Also Published As

Publication number Publication date
EP4084797A4 (en) 2024-02-21
US20230116114A1 (en) 2023-04-13
CA3161867A1 (en) 2021-07-08
EP4084797A1 (en) 2022-11-09
KR20220123406A (ko) 2022-09-06
WO2021138314A1 (en) 2021-07-08
CN114929235A (zh) 2022-08-19
AU2020416203A1 (en) 2022-06-16
JP2023509453A (ja) 2023-03-08

Similar Documents

Publication Publication Date Title
BR112019007977A2 (pt) composto, composição farmacêutica, método de tratamento ou prevenção de câncer, e, uso de um composto
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
NZ765590A (en) Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
MA40290A1 (fr) Agents immunorégulateurs
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
BR112018013084A2 (pt) tratamentos de combinação compreendendo a administração de imidazopirazinonas
GEP20207149B (en) Allosteric modulators of nicotinic acetylcholine receptors
BR112012031337A2 (pt) derivados de 5-amino-3,6-di-hidro-1h-pirazin-2-ona úteis como inibidores de beta-secretase (bace)
NO20075322L (no) NPY antagonister, samt femstilling og anvendelse av samme
ZA201907746B (en) 6-5 fused rings as c5a inhibitors
BR112022011123A2 (pt) Composto, processo para a preparação de um composto, usos de um composto, métodos para o tratamento de câncer e invenção
BR112018013247A2 (pt) tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos
MX2022001874A (es) Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos.
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
BR112021022380A2 (pt) Inibidores de jak
BR112021015616A2 (pt) Ligantes de pseudoquinase tyk2
MX2019007101A (es) Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
BR112021006319A2 (pt) compostos de indolinona para uso como inibidores de map4k1
BR112022000855A2 (pt) Moduladores de nlrp3
MX2019007102A (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
BR112022020147A2 (pt) Compostos para tratar a doença de huntington
BR112021021826A2 (pt) Terapias de combinação compreendendo os inibidores de apremilast e tyk2

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]